The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
The OncoAlert Newsletter is now out for June 23-29, 2023
AbstractBone is the most common site of breast cancer metastasis. Bone metastasis is incurable and is associated with severe morbidity. Utilizing an immunocompetent mouse model…
Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.
Dra. Barbara Melão entrevista o Dr. Nick James, oncologista no The Royal Master Hospital e professor do The Institute of Cancer Research, em Londres
CA: A Cancer Journal for Clinicians is ACS’ flagship clinical oncology journal publishing information about the prevention, early detection, and treatment of cancer.
At a recent Oncologic Drugs Advisory Committee (ODAC) Meeting, the U.S. Food and Drug Administration (FDA) laid out its rationale for rejecting the supplem
This is the recording of a lecture delivered to the National Breast Cancer Coalition (NBCC), a patient advocacy group focused on empowering patients with bre…
View this file, and add comments too.
Purpose In early-stage non-small cell lung cancer (NSCLC), post-treatment mortality may influence the comparative effectiveness of surgery and stereotactic body radiotherapy (SBRT), with implications for…
This study examines the potential benefits of aspirin as adjuvant therapy for survivors of early breast cancer.
Nature – Browser plug-in alerts users when studies — or their references — have been posted on a site known for raising integrity concerns.